Ignite Creation Date:
2024-05-05 @ 5:27 PM
Last Modification Date:
2024-10-26 @ 9:32 AM
Study NCT ID:
NCT00459004
Status:
COMPLETED
Last Update Posted:
2009-04-07
First Post:
2007-04-10
Brief Title:
Japanese Dose-Response Study of Rimonabant in Obese Patients
Sponsor:
Sanofi
Organization:
Sanofi
Study Overview
Official Title:
A Dose-Response Relationship Study of SR141716 in Obese Patients
Status:
COMPLETED
Status Verified Date:
2009-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The primary objective is to verify the dose-response relationship of rimonabant on body weight change
The secondary objectives are to compare the effect of 3 doses of SR141716 to placebo on body weight loss and on secondary criteria associated with comorbidities and to evaluate the safety and the pharmacokinetics of SR141716
The secondary objectives are to compare the effect of 3 doses of SR141716 to placebo on body weight loss and on secondary criteria associated with comorbidities and to evaluate the safety and the pharmacokinetics of SR141716
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None